Back to AF Calculator

AF Pathophysiology & Treatment Mechanisms

Understanding the mechanisms of atrial fibrillation — from atrial remodeling and thrombogenesis to how anticoagulation, rate control, antiarrhythmic drugs, catheter ablation, and lifestyle modification target each pathway.

Atrial Remodeling & AF Substrate

  • 1Atrial fibrosis creates heterogeneous conduction → re-entry circuits sustain AF
  • 2Electrical remodeling: shortened atrial refractory period → 'AF begets AF'
  • 3Structural remodeling: atrial dilation, fibrosis, and inflammation promote AF persistence
  • 4Pulmonary vein triggers initiate paroxysmal AF → progressive substrate develops over time
  • 5Autonomic nervous system modulation (vagal and sympathetic) triggers and maintains AF

Stroke Risk & Thrombogenesis

  • 1Virchow's triad in AF: stasis (LAA flow), endothelial dysfunction, hypercoagulability
  • 2Left atrial appendage (LAA) is the source of >90% of AF-related thrombi
  • 3CHA₂DS₂-VASc identifies additive stroke risk factors: each point ≈1.5-2% annual stroke risk
  • 4DOACs inhibit Factor Xa (apixaban, rivaroxaban, edoxaban) or thrombin (dabigatran)
  • 5Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) — requires INR monitoring

Rate Control Mechanisms

  • 1AV node conduction slowing reduces ventricular response rate in AF
  • 2Beta-blockers: block catecholamine stimulation at the AV node → reduce HR
  • 3Non-DHP CCBs (diltiazem, verapamil): block L-type calcium channels in AV node → slow conduction
  • 4Digoxin: enhances vagal tone → slows AV conduction (less effective during exercise/high sympathetic tone)
  • 5Amiodarone: multi-channel blockade slows AV conduction — reserved for refractory cases

Antiarrhythmic Drug Mechanisms

  • 1Class IC (flecainide, propafenone): block fast Na+ channels → slow conduction velocity. Contraindicated with structural HD
  • 2Class III (sotalol, dofetilide, amiodarone): block K+ channels → prolong repolarization/refractoriness
  • 3Dronedarone: multi-channel blocker (like amiodarone but without iodine). Contraindicated in HFrEF and permanent AF
  • 4Amiodarone: blocks Na+, K+, Ca2+ channels + beta-receptors. Most effective AAD but significant toxicity (thyroid, lung, liver)
  • 5AAD selection depends on cardiac structure: no structural HD → broader options; HFrEF → amiodarone or dofetilide only

Catheter Ablation

  • 1Pulmonary vein isolation (PVI): electrically disconnects pulmonary veins — primary source of AF triggers
  • 2Techniques: radiofrequency ablation (point-by-point) or cryoballoon ablation (single-shot)
  • 3First-line option for symptomatic paroxysmal AF (EARLY-AF, STOP AF First trials)
  • 4CASTLE-AF: ablation improved survival in AF + HFrEF (HR 0.53 for mortality)
  • 5Recurrence rates: ~70% freedom from AF at 1 year for paroxysmal; lower for persistent AF

Lifestyle & Risk Factor Modification

  • 1Weight loss ≥10%: 6x greater probability of AF-free survival (LEGACY trial)
  • 2Alcohol reduction: even moderate alcohol increases AF risk by 8% per drink/day
  • 3OSA treatment: untreated OSA increases AF recurrence post-ablation and post-cardioversion
  • 4Exercise: moderate exercise reduces AF risk; extreme endurance exercise may increase AF risk
  • 5BP control, glycemic control, and smoking cessation reduce AF burden and improve outcomes

Guideline Reference

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149:e1-e156. doi:10.1161/CIR.0000000000001193